U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.600.00 (0.00%)
At close: 4:00PM EDT

0.60 +0.02 (3.43%)
After hours: 4:00PM EDT

People also watch
ANTHACRXALIMMRNSGALE
Full screen
Previous Close0.60
Open0.60
Bid0.58 x 400
Ask0.63 x 2600
Day's Range0.58 - 0.60
52 Week Range0.38 - 1.14
Volume139,505
Avg. Volume418,753
Market Cap40.94M
Beta0.61
PE Ratio (TTM)-2.90
EPS (TTM)-0.21
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    Ampio Completes Enrollment of Patients in 12-Week Pivotal Trial

    ENGLEWOOD, Colo., Sept. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces the completion of enrollment and dosing of patients in their pivotal single injection study on the "unmet medical need" of severe osteoarthritis of the knee (OAK).  These patients experience not only pain but also the loss of function and diminished quality of life. The primary endpoint of this pivotal trial follows the Osteoarthritis Research Society International (OARSI) guidance, utilizing the Outcome Measures in Rheumatology Clinical Trials (OMERACT) OMERACT-OARSI responder rate to address the signs and symptoms of severe OAK. Michael Macaluso, Ampio's CEO, noted, "Announcing the close of enrollment so quickly speaks to the unmet medical need.

  • PR Newswire14 days ago

    Ampio Pharmaceuticals, Inc. Announces Annual Shareholder Meeting

    ENGLEWOOD, Colo. , Sept. 8, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...

  • PR Newswire15 days ago

    Ampio Pharmaceuticals, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

    ENGLEWOOD, Colo. , Sept. 7, 2017 /PRNewswire/ --   Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...